United Therapeutics CEO Martine Rothblatt sells $4.79m in stock By Investing.com

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (), sold common stock totaling approximately $4.79 million on August 13, 2026. The sales followed the exercise of stock options for an equal number of shares.

Ms. Rothblatt disposed of 9,500 shares of United Therapeutics common stock through a series of transactions on the reported date. The shares were sold at prices ranging from $499.46 to $512.64. The total value received from these sales amounted to $4,790,316. The stock currently trades at approximately $500, reflecting a remarkable 60% gain over the past year.

These sales were preceded by Ms. Rothblatt’s acquisition of 9,500 shares of common stock through the exercise of stock options. These options were exercised at a price of $135.42 per share, representing a total value of $1,286,489. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors can access detailed valuation metrics and a comprehensive Pro Research Report for UTHR on the platform.

Both the exercise of stock options and the subsequent sale of shares were carried out under a pre-arranged 10b5-1 trading plan. This plan was adopted by Ms. Rothblatt on November 7, 2025, and is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, all of which are set to expire on March 15, 2027.

Following these reported transactions, Ms. Rothblatt beneficially owns 324,443 shares indirectly through a family trust. She also holds other shares directly and indirectly through her spouse and various family trusts.

In other recent news, United Therapeutics reported its second-quarter 2026 earnings, revealing earnings per share of $7.27, which surpassed Wall Street’s estimate of $7.09. However, the company experienced a revenue shortfall, posting $783.3 million against the anticipated $807.05 million. This revenue miss of approximately 2.9% has drawn significant attention from investors. Additionally, United Therapeutics has decided not to affirm its previous sales guidance for Tyvaso, a development that has added to the cautious sentiment surrounding the company.

In response to these financial results, BofA Securities adjusted its price target for United Therapeutics, lowering it from $613 to $559, while maintaining a Neutral rating on the stock. The earnings report and subsequent analyst actions reflect mixed sentiment, with emphasis on the revenue miss despite the earnings beat. These developments are shaping investor perceptions and are key considerations for those following United Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.